Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Zealand Pharma AS's Average Total Inventories for the quarter that ended in Sep. 2024 was kr0.80 Mil. Zealand Pharma AS's Revenue for the
three
months ended in Sep. 2024 was kr4.42 Mil.
Zealand Pharma AS's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.18.
Zealand Pharma AS's Inventory-to-Revenue for the quarter that ended in Sep. 2024
increased
from Jun. 2024 (0.05) to Jun. 2024 (0.18)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Zealand Pharma AS's Inventory Turnover for the quarter that ended in Sep. 2024 was -8.24.
Zealand Pharma AS Inventory-to-Revenue Historical Data
The historical data trend for Zealand Pharma AS's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zealand Pharma AS's Inventory-to-Revenue
For the Biotechnology subindustry, Zealand Pharma AS's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Inventory-to-Revenue falls into.
Zealand Pharma AS Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Zealand Pharma AS's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (CHIX:ZEALc) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Zealand Pharma AS's Days Inventory for the
three
months ended in Sep. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Zealand Pharma AS's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:ZEALC has been successfully added to your 